A new research project is aiming to uncover why some cases of myeloma are more aggressive and harder to treat.
The three-year study, led by Dr John Jones at Brighton and Sussex Medical School and funded by the Sussex Cancer Fund, will investigate a genetic fault known as gain(1q), found in around 40 per cent of people with multiple myeloma.
"We’re proud to back work that could lead to smarter, more personalised treatments, not just for patients here in Sussex, but for people facing myeloma everywhere."
Gain(1q) is linked to faster disease progression and poorer outcomes in myeloma patients, but the exact reasons behind its impact remain unclear.
The Sussex Cancer Fund is investing nearly £50,000 in the project, which will collect samples from patients across Eastbourne, Hastings, and Brighton.
Researchers will use gene sequencing, protein analysis, and computer modelling to study how the mutation changes the disease.
Dr Jones said: "This funding allows us to take a deep dive into what makes gain(1q) such a game-changer in myeloma.
"We hope our work will lead to better, more targeted options for patients with high-risk disease."
The study supports the Sussex Cancer Fund’s mission to fund pioneering research and create opportunities for patients in Sussex to participate in clinical studies.
The charity said every donation helps advance cancer care and research.
Share